More Rohto Pharmaceutical Co., Ltd. news
Rohto Pharmaceutical Co., Ltd.TSE: 4527

Medium- to Long-Term Growth Strategy 2026,October 5, 2026

Oct 5, 2026 at 1:00 AM EDT · Issued by Rohto Pharmaceutical Co., Ltd. via TDnet

Filed with TSE · Oct 5, 2026 at 1:00 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/medium-to-long-term-growth-strategy-2026october-5-2026

Rohto Pharmaceutical Co., Ltd. on 6ix

Story so far

  • Medium- to Long-Term Growth Strategy 2026Oct 2, 2026

Earlier from Rohto Pharmaceutical

  • Medium- to Long-Term Growth Strategy 2026Oct 1
  • Management Strategy BriefingOct 1
  • バージャー病、膠原病により生じる難治性虚血性(非動脈硬化性)下肢潰瘍に対するRE-01細胞治療の第II相医師主導治験を開始Sep 15
  • Notice Regarding the Status of Repurchase of Shares and Completion of RepurchaseSep 15
  • Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological DiseasesSep 1
All Rohto Pharmaceutical news releases↗

Follow Rohto Pharmaceutical into a list and get an email when it puts out news.

Follow Rohto Pharmaceutical
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer